Market Overview

UPDATE: J.P. Morgan Downgrades Johnson & Johnson to Neutral on Trading Premium

Share:
Related JNJ
A Checkup On A Big Healthcare ETF
How To Build A Defensive Portfolio
Retirement Strategy: Having Cash Is Not A Sin, It Is Smart! (Seeking Alpha)

In a report published Monday, J.P. Morgan analyst Michael Weinstein downgraded the rating on Johnson & Johnson (NYSE: JNJ) from Overweight to Neutral, but raised the price target from $77.00 to $83.00.

In the report, Weinstein noted, “Last June, J&J was trading at a 5% discount to the sum-of-its-parts; now the shares trade at an 8% premium after a 30% run (and $54B in increased market cap). As good as Pharma and Consumer Staples stocks have been, J&J of late has been even better; and while fundamentals have improved at J&J, at $82 we think this is much more reflected in the name.”

Johnson & Johnson closed on Friday at $82.04.

Latest Ratings for JNJ

DateFirmActionFromTo
Feb 2016Deutsche BankMaintainsBuy
Jan 2016JefferiesMaintainsHold
Dec 2015Atlantic EquitiesInitiates Coverage onNeutral

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Downgrades Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters